AUROBAC THERAPEUTICS

Scientific file / structure

Structure name:

AUROBAC THERAPEUTICS

Address:

29 Avenue Tony Garnier
69007 Lyon
FRANCE


https://aurobac-tx.com/
contact@aurobac-tx.com

Area of intervention:

Antibiotics and alternative therapies, Clinical trials, Technological innovations and "omics", Microorganisms and host interactions/response, Pathology

Unity;

/

Team name:

/

Responsible:
(Unit director / head of structure)

Florence SEJOURNE (CEO)

Type of structure:

Biotech

Region:

Auvergne-Rhône-Alpes

City:

Lyon

Description:​

AUROBAC THERAPEUTICS is a biotech company founded as a joint venture by Boehringer Ingelheim, a leading research-driven biopharmaceutical company, the life science company Evotec SE and bioMérieux, a world leader in in vitro diagnostics, to create the next generation of products to fight AntiMicrobial Resistance (AMR). AUROBAC plans to work to shift the strategy related to antibiotic treatment regimens, which now leans heavily on empirical approaches using broad-spectrum and unfocused medicines. The goal is to turn this into a precision approach, using new highly effective and targeted modalities, combined with rapid and actionable diagnostics to quickly identify pathogens and their resistance patterns, and supported by new economic models.